A multi-centre study of the efficacy and safety of pravastatin in hypercholesterolaemic patients with non-insulin-dependent diabetes mellitus

References

• American Diabetes Association. Consensus statement: Role of cardiovascular risk factors in prevention and treatment of macrovascular disease in diabetes. Diabetes Care 1989; 12: 573–5791. American Diabetes Association. Consensus statement: Role of cardiovascular risk factors in prevention and treatment of macrovascular disease in diabetes. Diabetes Care 1989; 12: 573–579
   PubMed Web of Science ®Google Scholar
• Ballard D. J., Melton L. J., Dwyer M. S., Trautman J. C., Chu C-P., O'Fallon W. M., Palumbo P. J. Risk factors for diabetic retinopathy: a population-based study in Rochester, Minnesota. Diabetes Care 1986; 9: 334–3422. Ballard D. J., Melton L. J., Dwyer M. S., Trautman J. C., Chu C-P., O'Fallon W. M., Palumbo P. J. Risk factors for diabetic retinopathy: a population-based study in Rochester, Minnesota. Diabetes Care 1986; 9: 334–342
   PubMed Web of Science ®Google Scholar
• Barrett-Connor E., Wingard D. L. Sex differential in ischemic heart disease mortality rates in diabetics: a prospective population-based study. Am. J. Epidemiol. 1983; 118: 489–4963. Barrett-Connor E., Wingard D. L. Sex differential in ischemic heart disease mortality rates in diabetics: a prospective population-based study. Am. J. Epidemiol. 1983; 118: 489–496
   PubMed Web of Science ®Google Scholar
• Chait A., Bierman E. L. Pathogenesis of macrovascular disease in diabetes. Joslin's Diabetes Mellitus 13th edn., C. R. Kahn, G. C. Weir. Lea & Febiger, Philadelphia 1994; 6484. Chait A., Bierman E. L. Pathogenesis of macrovascular disease in diabetes. Joslin's Diabetes Mellitus 13th edn., C. R. Kahn, G. C. Weir. Lea & Febiger, Philadelphia 1994; 648
   Google Scholar
• Crouse J. R. Hypertriglyceridemia: a contraindication to the use of bile acid binding resins. Am. J. Med. 1987; 83: 243–2485. Crouse J. R. Hypertriglyceridemia: a contraindication to the use of bile acid binding resins. Am. J. Med. 1987; 83: 243–248
   PubMed Web of Science ®Google Scholar
• Diabetes Drafting Group. Prevalence of small vessel and large vessel disease in diabetic patients from 14 centers: the World Health Organization Multinational Study of Vascular Disease in Diabetics. Diabetologia 1985; 28: 615–6406. Diabetes Drafting Group. Prevalence of small vessel and large vessel disease in diabetic patients from 14 centers: the World Health Organization Multinational Study of Vascular Disease in Diabetics. Diabetologia 1985; 28: 615–640
   PubMedGoogle Scholar
• Friedewald W. T., Levy R. I., Fredrickson D. S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultra-centrifuge. Clin. Chem. 1972; 18: 499–5027. Friedewald W. T., Levy R. I., Fredrickson D. S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultra-centrifuge. Clin. Chem. 1972; 18: 499–502
   PubMed Web of Science ®Google Scholar
• Garg A., Grundy S. M. Lovastatin for lowering cholesterol levels in non-insulin-dependent diabetes mellitus. N. Engl. J. Med. 1988; 318: 81–868. Garg A., Grundy S. M. Lovastatin for lowering cholesterol levels in non-insulin-dependent diabetes mellitus. N. Engl. J. Med. 1988; 318: 81–86
   PubMed Web of Science ®Google Scholar
• Gurian H., Aldersberg D. The effect of large dose of nicotinic acid on circulating lipids and carbohydrate tolerance. Am. J. Med. Sci. 1959; 237: 12–229. Gurian H., Aldersberg D. The effect of large dose of nicotinic acid on circulating lipids and carbohydrate tolerance. Am. J. Med. Sci. 1959; 237: 12–22
   PubMed Web of Science ®Google Scholar
• Howard B. V. Lipoprotein metabolism in diabetes mellitus. J. Lipid Rex 1987; 28: 613–62810. Howard B. V. Lipoprotein metabolism in diabetes mellitus. J. Lipid Rex 1987; 28: 613–628
   PubMed Web of Science ®Google Scholar
• Jarrett R. J., McCartney P., Keen H. The Bedford Survey: ten year mortality rates in newly diagnosed diabetics, borderline and normoglycemic controls and risk indices for coronary heart disease in borderline diabetics. Diabetologia 1982; 22: 79–8411. Jarrett R. J., McCartney P., Keen H. The Bedford Survey: ten year mortality rates in newly diagnosed diabetics, borderline and normoglycemic controls and risk indices for coronary heart disease in borderline diabetics. Diabetologia 1982; 22: 79–84
   PubMed Web of Science ®Google Scholar
• Jungnickel P. W., Cantral K. A., Maloley P. A. Pravastatin: a new drug for the treatment of hypercholesterolemia. Clin. Pharm. 1992; 11: 677–68912. Jungnickel P. W., Cantral K. A., Maloley P. A. Pravastatin: a new drug for the treatment of hypercholesterolemia. Clin. Pharm. 1992; 11: 677–689
   PubMedGoogle Scholar
• Kahn S. E., Beard J. C., Schwartz M. W., Ward W. K., Ding H. L., Bergman R. N., Toborsky G. J., Jr., Porte D., Jr. Increased β-cell secretory capacity as mechanism for islet adaptation to nicotinic acid-induced insulin resistence. Diabetes 1989; 38: 562–56813. Kahn S. E., Beard J. C., Schwartz M. W., Ward W. K., Ding H. L., Bergman R. N., Toborsky G. J., Jr., Porte D., Jr. Increased β-cell secretory capacity as mechanism for islet adaptation to nicotinic acid-induced insulin resistence. Diabetes 1989; 38: 562–568
   PubMed Web of Science ®Google Scholar
• Klein R., Klein B. E. K., Moss S. E., Davis M. D., DeMets D. L. Glycosylated hemoglobin predicts the incidence and progression of diabetic retinopathy. J.A.M.A. 1988; 260: 2864–287114. Klein R., Klein B. E. K., Moss S. E., Davis M. D., DeMets D. L. Glycosylated hemoglobin predicts the incidence and progression of diabetic retinopathy. J.A.M.A. 1988; 260: 2864–2871
   PubMed Web of Science ®Google Scholar
• Kiss O., Von Bergmann K., Gnasso A., Augustin J. Effect of gemfibrozil on biliary lipid metabolism in normolipidemic subjects. Metabolism 1985; 34: 74–8215. Kiss O., Von Bergmann K., Gnasso A., Augustin J. Effect of gemfibrozil on biliary lipid metabolism in normolipidemic subjects. Metabolism 1985; 34: 74–82
   PubMed Web of Science ®Google Scholar
• Lopes-Virella M. R., Stone P., Ellis S., Colwell J. A. Cholesterol determination in high-density lipoprotein separated by three different methods. Clin. Chem. 1977; 23: 882–88516. Lopes-Virella M. R., Stone P., Ellis S., Colwell J. A. Cholesterol determination in high-density lipoprotein separated by three different methods. Clin. Chem. 1977; 23: 882–885
   PubMed Web of Science ®Google Scholar
• Molner G. D., Berge K. G., Rosevear J. W., McGuckin W. F., Achor W. P. The effect of nicotinic acid in diabetes mellitus. Metabolism 1964; 13: 181–18917. Molner G. D., Berge K. G., Rosevear J. W., McGuckin W. F., Achor W. P. The effect of nicotinic acid in diabetes mellitus. Metabolism 1964; 13: 181–189
   PubMed Web of Science ®Google Scholar
• Parthasarathy S., Young S. G., Witztum J. L., Pittman R. C., Steinberg D. Probucol inhibits oxidative modification of low density lipoprotein. J. Clin. Invest. 1986; 77: 641–64418. Parthasarathy S., Young S. G., Witztum J. L., Pittman R. C., Steinberg D. Probucol inhibits oxidative modification of low density lipoprotein. J. Clin. Invest. 1986; 77: 641–644
   PubMed Web of Science ®Google Scholar
• Pierides A. M., Alvarez-Ude F., Kerr D. N. S., Skillen A. W. Clofibrate-induced muscle damage in patients with chronic renal failure. Lancet 1975; 2: 1279–128219. Pierides A. M., Alvarez-Ude F., Kerr D. N. S., Skillen A. W. Clofibrate-induced muscle damage in patients with chronic renal failure. Lancet 1975; 2: 1279–1282
   PubMed Web of Science ®Google Scholar
• Pyörälä K., Laakso M., Uusitupa K. Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metab. Rev. 1987; 3: 463–52420. Pyörälä K., Laakso M., Uusitupa K. Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metab. Rev. 1987; 3: 463–524
   PubMedGoogle Scholar
• Reaven G. M. Non-insulin-dependent diabetes mellitus, abnormal lipoprotein metabolism, and atherosclerosis. Metabolism 1987; 36: 1–8, Suppl. 121. Reaven G. M. Non-insulin-dependent diabetes mellitus, abnormal lipoprotein metabolism, and atherosclerosis. Metabolism 1987; 36: 1–8, Suppl. 1
   PubMed Web of Science ®Google Scholar
• Steiner G. Atherosclerosis, the major complication of diabetes. Adv. Exp. Med. Biol. 1985; 189: 277–29722. Steiner G. Atherosclerosis, the major complication of diabetes. Adv. Exp. Med. Biol. 1985; 189: 277–297
   PubMed Web of Science ®Google Scholar
• Stern M. P., Patterson J. K., Haffner S. M., Hazuda H. P., Mitchell B. D. Lack of awareness and treatment of hyperlipidemia in type II diabetes in a community survey. J.A.M.A. 1989; 262: 360–36423. Stern M. P., Patterson J. K., Haffner S. M., Hazuda H. P., Mitchell B. D. Lack of awareness and treatment of hyperlipidemia in type II diabetes in a community survey. J.A.M.A. 1989; 262: 360–364
   PubMed Web of Science ®Google Scholar
• Umeda R, Watanabe J., Inoue K., Hisatomi A., Mimura K., Yamauchi T., Sako Y., Kunisaki M., Yajiri Y., Nawata H. Effect of pravastatin on serum lipids, apolipo-proteins and lipoprotein (a) in patients with non-insulin-dependent diabetes mellitus. Endocrinol. Jpn. 1992; 39: 45–5024. Umeda R, Watanabe J., Inoue K., Hisatomi A., Mimura K., Yamauchi T., Sako Y., Kunisaki M., Yajiri Y., Nawata H. Effect of pravastatin on serum lipids, apolipo-proteins and lipoprotein (a) in patients with non-insulin-dependent diabetes mellitus. Endocrinol. Jpn. 1992; 39: 45–50
   PubMedGoogle Scholar
• Yoshino G., Kazumi T., Iwai M., Matsushita M., Matsuba K., Uenoyama R., Iwatani L., Baba S. Long-term treatment of hypercholesterolemic non-insulin-dependent diabetes mellitus (NIDDM) with pravastatin (CS-514). Atherosclerosis 1989; 75: 67–7225. Yoshino G., Kazumi T., Iwai M., Matsushita M., Matsuba K., Uenoyama R., Iwatani L., Baba S. Long-term treatment of hypercholesterolemic non-insulin-dependent diabetes mellitus (NIDDM) with pravastatin (CS-514). Atherosclerosis 1989; 75: 67–72
   PubMed Web of Science ®Google Scholar